In NSCLC, second and third-generation EGFR-TK inhibitors were prepared for tumor cells with the T790M gatekeeper mutation and PI3K/AKT/mTOR inhibitors were under clinical trials [24,25,26]. Here, EGFR is linked to neoplasm.